TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Sees Large Growth in Short Interest

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) saw a significant increase in short interest in December. As of December 31st, there was short interest totalling 83,800 shares, an increase of 45.5% from the December 15th total of 57,600 shares. Based on an average daily volume of 37,300 shares, the days-to-cover ratio is currently 2.2 days. Currently, 2.4% of the company’s stock are short sold.

Wall Street Analysts Forecast Growth

Several research firms have commented on TLSI. Roth Capital raised TriSalus Life Sciences to a “strong-buy” rating in a research report on Monday, November 11th. Roth Mkm assumed coverage on shares of TriSalus Life Sciences in a report on Monday, November 11th. They issued a “buy” rating and a $11.00 target price on the stock. Canaccord Genuity Group reduced their price target on shares of TriSalus Life Sciences from $12.00 to $11.00 and set a “buy” rating for the company in a research report on Friday, November 15th. Cantor Fitzgerald began coverage on shares of TriSalus Life Sciences in a research report on Tuesday, December 17th. They set an “overweight” rating and a $10.00 price objective on the stock. Finally, Northland Capmk raised shares of TriSalus Life Sciences to a “strong-buy” rating in a report on Friday, October 25th. Seven analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, TriSalus Life Sciences currently has an average rating of “Buy” and a consensus price target of $11.79.

TriSalus Life Sciences Stock Performance

TLSI traded up $0.03 during trading on Thursday, hitting $4.83. The stock had a trading volume of 11,979 shares, compared to its average volume of 20,920. TriSalus Life Sciences has a twelve month low of $3.50 and a twelve month high of $10.42. The firm has a market capitalization of $147.27 million, a P/E ratio of -1.94 and a beta of 0.51. The company’s 50-day moving average price is $4.41 and its 200 day moving average price is $4.78.

Insiders Place Their Bets

In other news, major shareholder Equity Ab Frankenius acquired 62,972 shares of the company’s stock in a transaction on Tuesday, December 17th. The shares were bought at an average price of $3.97 per share, with a total value of $249,998.84. Following the completion of the acquisition, the insider now owns 6,230,748 shares in the company, valued at $24,736,069.56. This trade represents a 1.02 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Over the last quarter, insiders have purchased 70,012 shares of company stock valued at $281,235. 32.80% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in TLSI. Walleye Capital LLC acquired a new position in TriSalus Life Sciences during the 3rd quarter worth approximately $66,000. Virtu Financial LLC purchased a new stake in shares of TriSalus Life Sciences in the third quarter valued at approximately $92,000. Vestcor Inc acquired a new position in TriSalus Life Sciences during the third quarter worth $108,000. MSD Partners L.P. purchased a new position in TriSalus Life Sciences in the third quarter worth $184,000. Finally, Geode Capital Management LLC raised its position in TriSalus Life Sciences by 45.4% in the third quarter. Geode Capital Management LLC now owns 200,427 shares of the company’s stock worth $924,000 after acquiring an additional 62,542 shares in the last quarter. 2.58% of the stock is currently owned by institutional investors and hedge funds.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.